Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME MS: Cellcept + Avonex in Early MS
NCT00223301Phase 3Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Avonex + Cellcept with Avonex + Placebo (2 arms). Primary endpoint: Safety and Tolerability of Cellcept + Avonex at 1 year. Started Jul 2004; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00223301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223301.